Organon & Co. (NYSE:OGN) Shares Purchased by Versant Capital Management Inc

Versant Capital Management Inc boosted its stake in shares of Organon & Co. (NYSE:OGNFree Report) by 92.2% in the 4th quarter, Holdings Channel reports. The fund owned 2,760 shares of the company’s stock after buying an additional 1,324 shares during the period. Versant Capital Management Inc’s holdings in Organon & Co. were worth $41,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Prospera Private Wealth LLC acquired a new position in shares of Organon & Co. in the 3rd quarter valued at $25,000. William B. Walkup & Associates Inc. purchased a new position in Organon & Co. in the second quarter valued at $31,000. Abich Financial Wealth Management LLC raised its position in shares of Organon & Co. by 5,646.3% in the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after acquiring an additional 2,315 shares during the period. Trust Co. of Vermont boosted its stake in shares of Organon & Co. by 109.4% during the 3rd quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock worth $50,000 after acquiring an additional 1,372 shares in the last quarter. Finally, Eastern Bank purchased a new stake in shares of Organon & Co. during the 3rd quarter worth about $55,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Price Performance

Shares of NYSE OGN opened at $15.49 on Tuesday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm has a fifty day moving average of $15.54 and a 200 day moving average of $18.51. The firm has a market cap of $3.99 billion, a PE ratio of 3.07, a PEG ratio of 0.81 and a beta of 0.76. Organon & Co. has a one year low of $13.87 and a one year high of $23.10.

Organon & Co. (NYSE:OGNGet Free Report) last released its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.78 EPS. As a group, research analysts predict that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were given a $0.28 dividend. The ex-dividend date was Tuesday, November 12th. This represents a $1.12 annualized dividend and a dividend yield of 7.23%. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Analyst Ratings Changes

Separately, Evercore ISI raised Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

View Our Latest Report on Organon & Co.

About Organon & Co.

(Free Report)

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Further Reading

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGNFree Report).

Institutional Ownership by Quarter for Organon & Co. (NYSE:OGN)

Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.